BTIG upgraded Sensenonics Holdings (NYSE American:SENS) to “buy” from “neutral” with a price target of $1, citing a commercial collaboration with Ascensia Diabetes Care, a financing agreement with Ascensia’s parent, PHC...
William Blair initiated coverage of Beam Therapeutics (NASDAQ:BEAM) with an “outperform” rating and $33 fair value estimate. The stock closed at $19.01 on Aug. 4. Beam is focused on base editing, a next-generation gene...
William Blair launched coverage of Poseida Therapeutics (NASDAQ:PSTX) with an “outperform” rating and fair value estimate of $39. The stock closed at $12.98 on Aug. 3. “In our view, Poseida’s broad suite of platform...
H.C. Wainwright initiated coverage of Lumos Pharma (NASDAQ:LUMO) with a “buy” rating and $33 price target. The stock closed at $13.80 on Aug. 3. Analyst Edward White writes that the company’s LUM-201 drug candidate is...
Stifel launched coverage of Nkarta (NASDAQ:NKTX) with a “buy” rating and 12-month target price of $41. The stock closed at $26.58 on Aug. 3. Nkarta is focused on the discovery, development, and potential...
Stifel initiated coverage of Geron (NASDAQ:GERN) with a “buy” rating and $3 price target. The stock closed at $1.59 on July 31. Geron is focused on the development and potential commercialization of a single product...
Maxim Group raised its price target for Onconova Therapeutics (NASDAQ:ONTX) to $3 from $1.25 after the company announced that the required number of survival events for the pivotal Phase 3 INSPIRE study of IV rigosertib...
H.C. Wainwright launched coverage of Sierra Oncology (NASDAQ:SRRA) with a “buy” rating and $20 price target. The stock closed at $12.46 on July 29. Sierra Oncology is in the midst of a Phase 3 MOMENTUM study with its...
Dawson James Securities downgraded Soligenix (NASDAQ:SNGX) to “neutral” from “buy” and reduced its price target to $2 from $3, citing a model update for dilution. The stock closed at $2.13 on July 27. “We have updated...
Maxim Group raised its price target for Heat Biologics (NASDAQ:HTBX) to $5 from $2, citing the potential of the company’s vaccine platform to produce long-lasting cellular immunity against COVID-19. The stock closed at...